Tocriscreen™ PRO Custom Compound Library Service

As well as requesting a completely custom library, the Tocriscreen PRO service also allows you to select a pre-defined list of compounds. Currently available lists are:

• COVID-19 Compounds – this list is comprised of a subset of products from the Tocriscreen 2.0 compound library, for key targets within the SARS-CoV-2 viral life cycle and compounds that have been linked to coronaviruses in the scientific literature. The library is available in 10 mM DMSO solution (50 μL - 1 mL) or as dry powder (2 - 10 mg).
• Additional New Products – If you previously purchased the Tocriscreen Plus, Plus Mini or Plus Micro Compound Libraries (Cat. Nos. 5840, 5481 and 6455, respectively), this list provides you with compounds recently added to the Tocriscreen 2.0 compound library list. These compounds will be supplied pre-dissolved in 10 mM DMSO, at a minimum volume of 250 μL.

 

The Tocris scientific team are ready to help you with choosing compounds and designing your bioactive compound library to fit your research needs. To help our team get started on your inquiry, please provide as much information as possible about your required compound format, research areas and targets, and if you require one of the pre-defined lists outlined above.

Please submit your requirements through the compound library inquiry form.

 

 

Major Research Areas Covered By Tocriscreen PRO

The Tocriscreen 2.0 Compound Library contains bioactive compounds covering a diverse range of biomedical research areas; Neuroscience (41%), Cancer (32%), Endocrinology (10%), Cardiovascular (6%), Immunology (6%), Stem Cells (4%), other research areas (2%).

 

Major Target Classes Covered By Tocriscreen PRO

The Tocriscreen 2.0 Compound Library contains bioactive compounds covering a diverse range of molecular targets; 7-TM receptors (GPCRs; 27%), non-kinase enzymes (21%), kinases including enzyme-linked receptors (20%), ion channels (13%), cell biology targets (9%), nuclear receptors (6%), and transporters and other pharmacological targets (5%).

 

Citations

Danish et al (2021) A cellular assay for the identification and characterization of connexin gap junction modulators. Int.J.Mol.Sci. 22 1417 PMID: 33572565 

Wazir et al (2021) Activity-based screening assay for mono-ADP-ribosylhydrolases. SLAS Discov. 26 67 PMID: 32527186

Yoon et al (2020) Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. BMB Rep. 53 166 PMID: 31964466

Duvall et al (2019) Small-molecule agonists of Ae. aegypti neuropeptide Y receptor block mosquito biting. Cell. 176 687 PMID: 30735632

Fiedler et al (2019) MAP4K4 inhibition promotes survival of human stem cell-derived cardiomyocytes and reduces infarct size in vivo. Cell Stem Cell. 24 579 PMID: 30853557 

Takeuchi et al (2019) Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor. PLoS One. 14 e0212233 PMID: 30779774

Mishra et al (2022) Improved loss-of-function CRISPR/Cas9 genome editing in human cells concomitant with inhibition of TGFβ signaling. Molecular Therapy: Nucleic Acid. 28  202 PMID: 35402072 

Jang et al (2018) Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function. J.Virol 92 e01441 PMID: 30282713

Heins-Marroquin et al (2019) Phenotypic assays in yeast and zebrafish reveal drugs that rescue ATP13A2 deficiency. Brain.Commun. 1 fcz019 PMID: 32954262

McBrinn et al (2018) Novel pharmacological actions of trequinsin hydrochloride improve human sperm cell motility and function. Br.J.Pharmacol. 176 4521 PMID: 31368510

Cheng et al (2022) A comprehensive phenotypic screening strategy to identify modulators of cargo translocation by the bacterial type IVB secretion system. mBio. 13 e0024022 PMID: 35258332

Tsukamoto et al (2018) Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction. PLoS One. 13 e0197664 PMID: 29782545

Collia et al (2018) A rapid phenotypic whole-cell screening approach for the identification of small-molecule inhibitors that counter β-lactamase resistance in Pseudomonas aeruginosa. SLAS Discov. 23 55 PMID: 28850797

Zeng et al (2021) Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase. Biochem.J. 478 2405 PMID: 34198322

Canal et al (2021) Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease. Biochem.J. 478 2465 PMID: 34198324

Murer et al (2022) Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern. Curr.Res.Virol.Sci. 3 100019 PMID: 35072124

Mitsui et al (2019) Identification of ryuvidine as a KDM5A inhibitor. Sci.Rep. 9 9952 PMID: 31289306

Ghasemi et al (2018) High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines. Oncotarget 9 26064 PMID: 29899842

Mirabelli et al (2021) Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. Proc.Natl.Acad.Sci.U.S.A. 118 e2105815118 PMID: 34413211

Anerillas et al (2022) A BDNF-TrkB autocrine loop enhances senescent cell viability. Nat.Commun. 13 6228 PMID: 36266274

Harris et al (2019) Deubiquitinases maintain protein homeostasis and survival of cancer cells upon glutathione depletion. Cell Metab. 29 1166 PMID: 30799286

Benítez et al (2022) Drug-like molecules with anti-trypanothione synthetase activity identified by high throughput screening. J.Enzyme Inhib.Med.Chem. 37 912 PMID: 35306933